Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and ...
CDK4/6 inhibitor plus endocrine therapy is an active treatment option for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer compared with chemotherapy ...
In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.
Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback